Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy:Results of the EUROCONDOR Clinical Trial

Simó, Rafael, Hernández, Cristina, Porta, Massimo, Bandello, Francesco, Grauslund, Jakob, Harding, Simon P., Aldington, Stephen J., Egan, Catherine, Frydkjaer-Olsen, Ulrik, García-Arumí, José, Gibson, Jonathan, Lang, Gabriele E., Lattanzio, Rosangela, Massin, Pascale, Midena, Edoardo, Ponsati, Berta, Ribeiro, Luísa, Scanlon, Peter, Lobo, Conceição, Costa, Miguel Ângelo and Cunha-Vaz, José (2019). Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy:Results of the EUROCONDOR Clinical Trial. Diabetes, 68 (2), pp. 457-463.


The primary objective of this study was to assess whether the topical administration of two neuroprotective drugs (brimonidine and somatostatin) could prevent or arrest retinal neurodysfunction in patients with type 2 diabetes. For this purpose, adults aged between 45 and 75 years with a diabetes duration ≥5 years and an Early Treatment of Diabetic Retinopathy Study (ETDRS) level of ≤35 were randomly assigned to one of three arms: placebo, somatostatin, or brimonidine. The primary outcome was the change in implicit time (IT) assessed by multifocal electroretinography between baseline and at the end of follow-up (96 weeks). There were 449 eligible patients allocated to brimonidine (n = 152), somatostatin (n = 145), or placebo (n = 152). When the primary end point was evaluated in the whole population, we did not find any neuroprotective effect of brimonidine or somatostatin. However, in the subset of patients (34.7%) with preexisting retinal neurodysfunction, IT worsened in the placebo group (P < 0.001) but remained unchanged in the brimonidine and somatostatin groups. In conclusion, the topical administration of the selected neuroprotective agents appears useful in preventing the worsening of preexisting retinal neurodysfunction. This finding points to screening retinal neurodysfunction as a critical issue to identify a subset of patients in whom neuroprotective treatment might be of benefit.

Publication DOI: https://doi.org/10.2337/db18-0682
Divisions: Life & Health Sciences
Life & Health Sciences > Optometry
Additional Information: © 2018 by the American Diabetes Association. http://www.diabetesjournals.org/content/license Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
Uncontrolled Keywords: Internal Medicine,Endocrinology, Diabetes and Metabolism
Full Text Link:
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
http://diabetes ... 57.article-info (Publisher URL)
Published Date: 2019-02-01
Authors: Simó, Rafael
Hernández, Cristina
Porta, Massimo
Bandello, Francesco
Grauslund, Jakob
Harding, Simon P.
Aldington, Stephen J.
Egan, Catherine
Frydkjaer-Olsen, Ulrik
García-Arumí, José
Gibson, Jonathan ( 0000-0002-9281-5244)
Lang, Gabriele E.
Lattanzio, Rosangela
Massin, Pascale
Midena, Edoardo
Ponsati, Berta
Ribeiro, Luísa
Scanlon, Peter
Lobo, Conceição
Costa, Miguel Ângelo
Cunha-Vaz, José



Version: Accepted Version

| Preview

Export / Share Citation


Additional statistics for this record